Skip to main content
Premium Trial:

Request an Annual Quote

Accuri Reels in $4M in New Investments

NEW YORK (GenomeWeb News) – Flow cytometry systems maker Accuri Cytometers has received $4 million in Series D financing from current and new investors, the company said today.

The Ann Arbor, Mich.-based firm said it plans to use the funds support manufacturing and marketing of its C6 Flow Cytometer and the CSampler, which is used to automate the C6.

This round of financing came from previous investors Fidelity Biosciences, Flagship Ventures, Baird Venture Partners, and Arboretum Ventures, and included an investment from InvestMichigan!, a program co-managed by Credit Suisse.

The company closed a $13 million Series C financing round in July 2008.

Accuri CEO Jennifer Baird said in a statement that the company plans to "build out our manufacturing and customer support capabilities in Michigan and to continue to expand our presence globally."

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.